sGC is a key signal transduction enzyme in the cardiovascular system and is not only impaired in HFpEF but also in a variety of diseases such as hypertension, pulmonary hypertension, chronic kidney disease, and erectile dysfunction, all of which are associated with impaired NO–sGC–cGMP signaling (Kemp-Harper and Feil, 2008; Schulz et al., 2008; Stasch et al., 2011; Klinger and Kadowitz, 2017). Here, SGCB is linked to pulmonary arterial hypertension.